These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20978369)

  • 1. The long and winding road to antibody therapeutics.
    McCafferty J
    MAbs; 2010; 2(5):459-60. PubMed ID: 20978369
    [No Abstract]   [Full Text] [Related]  

  • 2. Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies.
    Malesci A; Angelucci E; Bonifacio C; Sociale O; Omodei P; Repici A; Balzarini L; Danese S
    Inflamm Bowel Dis; 2009 Jun; 15(6):814-5. PubMed ID: 18831523
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.
    Jürgens M; Brand S; Filik L; Hübener C; Hasbargen U; Beigel F; Tillack C; Göke B; Ochsenkühn T; Seiderer J
    Inflamm Bowel Dis; 2010 Oct; 16(10):1634-6. PubMed ID: 20027647
    [No Abstract]   [Full Text] [Related]  

  • 4. Adalimumab for cutaneous metastatic Crohn's disease.
    Cury DB; Moss AC; Elias G; Nakao A
    Inflamm Bowel Dis; 2010 May; 16(5):723-4. PubMed ID: 19728388
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor necrosis factor inhibitors: following best practice.
    White B
    Manag Care; 2005 May; 14(5 Suppl):17-23. PubMed ID: 15962833
    [No Abstract]   [Full Text] [Related]  

  • 6. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications.
    Murdaca G; Colombo BM; Puppo F
    Drugs Today (Barc); 2011 Apr; 47(4):277-88. PubMed ID: 21573251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab for Mooren's ulcer.
    Cordero-Coma M; Benito MF; Fuertes CL; Antolín SC; García Ruíz JM
    Ophthalmology; 2009 Aug; 116(8):1589, 1589.e1. PubMed ID: 19651317
    [No Abstract]   [Full Text] [Related]  

  • 8. [Adalimumab therapy in Crohn's disdease].
    Baryshnikov EN; Lazebnik LB; Parfenov AI
    Eksp Klin Gastroenterol; 2009; (5):92-8. PubMed ID: 20205331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
    Licastro F; Chiappelli M; Ianni M; Porcellini E
    Int J Immunopathol Pharmacol; 2009; 22(3):567-72. PubMed ID: 19822073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab in the treatment of immune-mediated diseases.
    Lapadula G; Marchesoni A; Armuzzi A; Blandizzi C; Caporali R; Chimenti S; Cimaz R; Cimino L; Gionchetti P; Girolomoni G; Lionetti P; Marcellusi A; Mennini FS; Salvarani C
    Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):33-48. PubMed ID: 24774505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti TNF-alpha treatment for Crohn' disease: "ménage a trois".
    Danese S
    Curr Drug Targets; 2010 Feb; 11(2):136-7. PubMed ID: 20214597
    [No Abstract]   [Full Text] [Related]  

  • 12. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
    Sibilia J
    Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoclonal antibodies in chronic autoimmune inflammatory diseases].
    Semerano L; Boissier MC
    Med Sci (Paris); 2009 Dec; 25(12):1108-12. PubMed ID: 20035687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.
    Armuzzi A; Lionetti P; Blandizzi C; Caporali R; Chimenti S; Cimino L; Gionchetti P; Girolomoni G; Lapadula G; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Cimaz R
    Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):11-32. PubMed ID: 24774504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.
    Neri P; Zucchi M; Allegri P; Lettieri M; Mariotti C; Giovannini A
    Int Ophthalmol; 2011 Apr; 31(2):165-73. PubMed ID: 21287227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esophageal Crohn's disease treated successfully with adalimumab.
    Kwan LY; Conklin JL; Papadakis KA
    Inflamm Bowel Dis; 2007 May; 13(5):639-40. PubMed ID: 17221856
    [No Abstract]   [Full Text] [Related]  

  • 17. Adalimumab for the treatment of ankylosing spondylitis.
    Sieper J; Rudwaleit M; Braun J
    Expert Opin Pharmacother; 2007 Apr; 8(6):831-8. PubMed ID: 17425478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New approaches to treatment in immunology with monoclonal antibodies].
    Rubbert A; Diehl V
    Internist (Berl); 2001 Jun; 42(6):843, 846-53. PubMed ID: 11449631
    [No Abstract]   [Full Text] [Related]  

  • 19. [What is special about adalimumab?].
    Rodríguez-Blanco I; Toribio J
    Actas Dermosifiliogr; 2008 Feb; 99 Suppl 3():28-32. PubMed ID: 18680688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crohn's disease: Adalimumab improves quality of life.
    Papadakis KA
    Nat Rev Gastroenterol Hepatol; 2009 Apr; 6(4):200-1. PubMed ID: 19347008
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.